Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female gender;~* Age ≥18 years;~* Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1~* Histologically confirmed invasive breast cancer:~* Primary tumor greater than 1 cm diameter, measured by clinical examination and mammography or ultrasound.~* Any N,~* No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed);~* Over expression and/or amplification of HER2 in the invasive component of the primary tumor and confirmed by a certified laboratory prior to randomization.~* Known hormone receptor status.~* Hematopoietic status:~* CBC not less than .75 of institutional lower limit. Absolute neutrophil count ≥ 1,5 x 10\^9/L, Platelet count ≥ 100 x 10\^9/L, Hemoglobin at least 9 g/dl,~* Hepatic status:~Serum total bilirubin ≤ 2 x upper limit of normal (ULN). In the case of known Gilbert's syndrome, a higher serum total bilirubin (\< 1.5 x ULN) is allowed, Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 3.5 times ULN, Alkaline phosphatase ≤ 2.5 times ULN, • Renal status: Creatinine ≤ 1.5mg/dL,~• Cardiovascular: Baseline left ventricular ejection fraction (LVEF) ³ ≥50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan,~* Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential within 2-weeks (preferably 7 days) prior to randomization.~* Fertile patients must use effective contraception (barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not allowed)~* Signed informed consent form (ICF)~* Patient accepts to make available tumor samples for submission to central laboratory to conduct translational studies as part of this protocol.~Exclusion Criteria:~* Previous (less than 5 years) or current history of malignant neoplasms, except for curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ of the cervix.~* Patients with a prior malignancy diagnosed more than 5 years prior to randomization may enter the study.~* Preexisting peripheral neuropathy ≥ grade 2~* Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension (≥180/110), unstable diabetes mellitus, dyspnea at rest, or chronic therapy with oxygen;~* Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety;~* Unresolved or unstable, serious adverse events from prior administration of another investigational drug;~* Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of ICF;~* Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded;~* Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy other than the trial therapies);~* Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial;~* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab Emtansine, trastuzumab, lapatinib, paclitaxel, abraxane or their components;~* Pregnant or lactating women;~* Concomitant use of CYP3A4 inhibitors or inducers~* Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g. active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol~* Patients have an active infection and require IV or oral antibiotics.~* Pregnant or breast-feeding women~* Patients unwilling or unable to comply with the protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- T-DM1 + Lapatinib + Abraxane (Type: EXPERIMENTAL): T-DM1 intravenously (IV) every three weeks plus L orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.
- Trastuzumab + Pertuzumab + Paclitaxel (Type: ACTIVE_COMPARATOR): Trastuzumab IV weekly plus pertuzumab IV every 3 weeks for 6 weeks, followed by paclitaxel IV weekly for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete